SZN-043 preclinical data shows rapid, transient increases in hepatocyte proliferation and was well tolerated in non-clinical toxicology studiesSZN-1326 preclinical data...
REDWOOD CITY, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused...
Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive ProductSAN DIEGO, Oct. 10, 2022 (GLOBE NEWSWIRE)...
Announces Preliminary Financial Results for Third Quarter 2022WINTER SPRINGS, Fla., Oct. 10, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ:...
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent...
Successful Marketing Executive Joins Company to Build on Strategic Innovation InvestmentsNASHVILLE, Tenn., Oct. 10, 2022 (GLOBE NEWSWIRE) -- SmileDirectClub, Inc....
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker,...
FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide Commercial launch planned in Q1 2023...
Houston, Texas and Tuebingen, Germany, October 10, 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in...
Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST Clinical validation of PRAME...
POMPANO BEACH, FLORIDA., Oct. 10, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC PINK: BSEM), a leading regenerative medicine company...
Phase 3 Clinical Trial to Proceed to Second Interim Analysis Expected to Occur in 2023SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022...
First Genetically Modified (TALEN®-edited) Iovance TIL Therapy with Inactivated PD-1 Expression SAN CARLOS, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) --...
Poster presentation indicates new microgranule formulation elicited desired delayed release profile, offering protection at acidic pH and rapid release under...
DEVON, Pa., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing...
Complements Existing Allowance in the U.S. as Global Jurisdictions Recognize the Uniqueness of the TechnologyHINGHAM, Mass., Oct. 10, 2022 (GLOBE...
NEW YORK, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Clinical and pre-clinical data from across the company’s portfolio will be featured in four oral and six poster presentations Co-founder...
RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that...